Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance

"* Baseline~* Approximately 30 days after cytotoxic induction therapy~* End of treatment"

"* The first will be obtained with the initial blood and bone marrow collections, whenever possible.~* The second will be obtained at the time of re-biopsy to confirm remission."

Clinical Sequencing to determine clearance or persistence of leukemia-associate mutations performed at MGI CLIA lab